PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Claessen, H.* ; Strassburger, K.* ; Tepel, M.* ; Waldeyer, R.* ; Chernyak, N.* ; Jülich, F.* ; Albers, B.* ; Bächle, C.* ; Rathmann, W.* ; Meisinger, C. ; Thorand, B. ; Hunger, M. ; Schunk, M. ; Stark, R. ; Rückert, I.-M. ; Peters, A. ; Huth, C. ; Stöckl, D. ; Giani, G.* ; Holle, R. ; Icks, A.*

Medication costs by glucose tolerance stage in younger and older women and men: Results from the population-based KORA survey in Germany.

Exp. Clin. Endocrinol. Diabet. 121, 614-623 (2013)
DOI PMC
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
To estimate medication costs in individuals with diagnosed diabetes, undetected diabetes, impaired glucose regulation and normal blood glucose values in a population-based sample by age and sex.Using the KORA F4 follow-up survey, conducted in 2006-2008 (n=2611, age 40-82 years), we identified individuals' glucose tolerance status by means of an oral glucose tolerance test. We assessed all medications taken regularly, calculated age-sex specific medication costs and estimated cost ratios for total, total without antihyperglycemic drugs, and cardiovascular medication, using multiple 2-part regression models.Compared to individuals with normal glucose values, costs were increased in known diabetes, undetected diabetes and impaired glucose regulation, which was more pronounced in participants aged 40-59 years than in those aged 60-82 years (cost ratios for all medications: 40-59 years: 2.85; 95%-confidence interval: 1.78-4.54, 2.00; 1.22-3.29 and 1.53; 1.12-2.09; 60-82 years: 2.04; 1.71-2.43, 1.17; 0.90-1.51 and 1.09; 0.94-1.28). Compared to individuals with diagnosed diabetes, costs were significantly lower among individuals with impaired glucose regulation across all age and sex strata, also when antihyperglycemic medication was excluded (40-59 years: 0.60; 0.36-0.98, 60-82 years: 0.74; 0.60-0.90; men: 0.72; 0.56-0.93; women: 0.72; 0.54-0.96).We could quantify age- and sex-specific medication costs and cost ratios in individuals with diagnosed diabetes, undetected diabetes and impaired glucose regulation compared to those with normal glucose values, using data of a population-based sample, with oral glucose tolerance test-based identification of diabetes states. These results may help to validly estimate cost-effectiveness of screening and early treatment or prevention of diabetes.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
0.596
0.596
2
3
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Drug Costs ; Glucose Tolerance Status ; Age-sex-strata ; Population-based Survey; Prescription Drug Costs ; Diabetes-mellitus ; Care Costs ; Southern Germany ; Type-2 ; Diagnosis ; Outcomes ; Cohort ; Risk ; Interventions
Sprache englisch
Veröffentlichungsjahr 2013
HGF-Berichtsjahr 2013
ISSN (print) / ISBN 0947-7349
e-ISSN 1439-3646
Zeitschrift Experimental and Clinical Endocrinology & Diabetes
Quellenangaben Band: 121, Heft: 10, Seiten: 614-623 Artikelnummer: , Supplement: ,
Verlag Thieme
Verlagsort Stuttgart
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Epidemiology (EPI)
Institute of Health Economics and Health Care Management (IGM)
POF Topic(s) 30202 - Environmental Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Genetics and Epidemiology
PSP-Element(e) G-504000-006
G-504000-002
G-505300-002
G-501900-531
G-504000-001
G-501900-401
G-504090-001
PubMed ID 24122240
DOI 10.1055/s-0033-1354357
WOS ID WOS:000328122000007
Scopus ID 84889085251
Erfassungsdatum 2013-10-25
[➜Korrektur melden]